PUBLISHED ON: November 1, 2010 | Duration: 4 min, 23 sec
Sun Pharma head (investor relations) Uday Baldota says the change in the margins is largely due to change in the product and segment mix. There is no guidance going forward, but the performance has been in line with the company's expectation, he adds.
